Lophius Biosciences Launches Interactive T Cell Tools Product Finder and Online Order Portal
Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell-based research tools and diagnostic systems for functional assessment of pathogen/disease-reactive T cells, has launched of its new T Cell Tools product line together with its new e-commerce online order portal. The new web-based customer interface at www.Lophius.com has been designed to provide an intuitive product selection and online order platform accelerating the ability of customers to quickly identify and select products from Lophius’ continuously growing portfolio.
T Cell Tools comprise selected research reagents to allow easy and reliable T cell stimulation, as well as robust quantification and monitoring of cell mediated immune responses (CMI). Different antigens from various pathogens with a current focus on the human cytomegalovirus (HCMV) and Epstein-Barr Virus (EBV) are well coordinated and validated to jointly contribute to a standardized and reliable read-out system. Hence, the individual product modules of T Cell Tools offer modular and complementary solutions for optimal assay performance.
Today, T Cell Tools include, amongst, peptide pools, lysates an proteins, a panel of T-activated antigens - complete proteins that are formulated using Lophius’ proprietary T-activation technology platform facilitating uptake and processing of the proteins via the canonical MHC class-I cross-presentation pathway. As a result, clinically relevant effector cells of the CMI such as CD4- and CD8-positve T cells as well as NK, and NKT cells will be activated. Optionally, customers may also combine their antigens with a matching IFN-gamma ELISPOT T-Track basic kit to reach maximum sensitivity and specificity upon measuring pathogen specific T cells.
Lophius aims to quickly expand the panel of antigens, antibodies, conjugates and read-out options to offer its customers a very comprehensive panel of relevant and well coordinated tools in near future to booster T cell research. Customers include researchers and clinicians in the field of immunology, infectious diseases, transplantation, clinical virology, oncology, autoimmune diseases, gynecology, and intensive care who need optimal performance by using either the standardized in-vitro diagnostic kit T-Track CMV or an individually compiled T cell activity assay based on the robust T-Track technology.
“We are very excited to announce the launch of our e-commerce portal as we believe it will provide our customers greater access to Lophius’ products at their convenience,” said Dr Robert Phelps, CEO of Lophius Biosciences. “With our intuitive product finder, consumers can browse and order some of the most innovative T cell products on the market” added Prof. Ralf Wagner, Chairman of the Board.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...